Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients

A W J H Dielis; M Smid; H M H Spronk; A J H M Houben; K Hamulyák; A A Kroon; H Ten Cate; P W de Leeuw

doi:10.1111/j.1538-7836.2007.02577.x

Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients

A W J H Dielis
, M Smid
, H M H Spronk
, A J H M Houben
, K Hamulyák
, A A Kroon
, H Ten Cate^*
, P W de Leeuw

^*Corresponding author for this work

CARIM - Cardiovascular Research Institute Maastricht

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: In hypertensive patients, the activated renin-angiotensin system induces a prothrombotic state resulting from imbalance between coagulation and fibrinolysis. Although blood pressure cannot be regulated in therapy-resistant hypertensive patients, they may still be responsive to medication that attenuates the renin-angiotensin system.

OBJECTIVE: our objective was to study possible attenuating properties of angiotensin II type 1 receptor blockers (AT1RBs) on the prothrombotic state in therapy-resistant hypertensive patients, focusing on parameters of fibrinolysis and coagulation.

METHODS: Fourteen therapy-resistant hypertensive patients received AT1RB eprosartan infusion (45 and 150 microg kg(-1)) (study group), and 33 therapy-resistant hypertensive patients received saline (0.9%) infusion (control group) prior to renal angiography. Baseline values of parameters of coagulation and fibrinolysis were set at 1.00, and relative changes were calculated.

RESULTS: Plasminogen activator inhibitor type 1 (PAI-1) antigen showed non-significant decreases in both the study group (arterial 1.00-0.45, venous 1.00-0.42) and control group (arterial 1.00-0.84, venous 1.00-0.88). PAI-1 activity significantly decreased in the study group (arterial 1.00-0.72, venous 1.00-0.71) and control group (arterial 1.00-0.83, venous 1.00-0.94). In the study group, tissue-type plasminogen activator (t-PA) antigen decreased significantly (arterial 1.00-0.62, venous 1.00-0.67), whereas t-PA activity significantly increased (arterial 1.00-6.15, venous 1.00-2.66). In the control group, t-PA antigen remained unchanged. No changes were observed in blood pressure during and after infusion of eprosartan.

CONCLUSION: Therapy-resistant hypertensive patients show beneficial changes in fibrinolytic activity after infusion of a non-pressor dose of AT1RB.

Original language	English
Pages (from-to)	1509-15
Number of pages	7
Journal	Journal of Thrombosis and Haemostasis
Volume	5
Issue number	7
DOIs	https://doi.org/10.1111/j.1538-7836.2007.02577.x
Publication status	Published - Jul 2007

Keywords

Acrylates/pharmacology
Adult
Aged
Angiotensin II Type 1 Receptor Blockers/pharmacology
Blood Coagulation/drug effects
Case-Control Studies
Drug Resistance
Endothelial Cells/drug effects
Female
Fibrinolysis/drug effects
Humans
Hypertension/blood
Imidazoles/pharmacology
Male
Middle Aged
Thiophenes/pharmacology

Access to Document

10.1111/j.1538-7836.2007.02577.xLicence: Free access - publisher

Cite this

@article{b77db0db98524d43a83841884835a6cc,

title = "Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients",

abstract = "BACKGROUND: In hypertensive patients, the activated renin-angiotensin system induces a prothrombotic state resulting from imbalance between coagulation and fibrinolysis. Although blood pressure cannot be regulated in therapy-resistant hypertensive patients, they may still be responsive to medication that attenuates the renin-angiotensin system.OBJECTIVE: our objective was to study possible attenuating properties of angiotensin II type 1 receptor blockers (AT1RBs) on the prothrombotic state in therapy-resistant hypertensive patients, focusing on parameters of fibrinolysis and coagulation.METHODS: Fourteen therapy-resistant hypertensive patients received AT1RB eprosartan infusion (45 and 150 microg kg(-1)) (study group), and 33 therapy-resistant hypertensive patients received saline (0.9\%) infusion (control group) prior to renal angiography. Baseline values of parameters of coagulation and fibrinolysis were set at 1.00, and relative changes were calculated.RESULTS: Plasminogen activator inhibitor type 1 (PAI-1) antigen showed non-significant decreases in both the study group (arterial 1.00-0.45, venous 1.00-0.42) and control group (arterial 1.00-0.84, venous 1.00-0.88). PAI-1 activity significantly decreased in the study group (arterial 1.00-0.72, venous 1.00-0.71) and control group (arterial 1.00-0.83, venous 1.00-0.94). In the study group, tissue-type plasminogen activator (t-PA) antigen decreased significantly (arterial 1.00-0.62, venous 1.00-0.67), whereas t-PA activity significantly increased (arterial 1.00-6.15, venous 1.00-2.66). In the control group, t-PA antigen remained unchanged. No changes were observed in blood pressure during and after infusion of eprosartan.CONCLUSION: Therapy-resistant hypertensive patients show beneficial changes in fibrinolytic activity after infusion of a non-pressor dose of AT1RB.",

keywords = "Acrylates/pharmacology, Adult, Aged, Angiotensin II Type 1 Receptor Blockers/pharmacology, Blood Coagulation/drug effects, Case-Control Studies, Drug Resistance, Endothelial Cells/drug effects, Female, Fibrinolysis/drug effects, Humans, Hypertension/blood, Imidazoles/pharmacology, Male, Middle Aged, Thiophenes/pharmacology",

author = "Dielis, \{A W J H\} and M Smid and Spronk, \{H M H\} and Houben, \{A J H M\} and K Hamuly{\'a}k and Kroon, \{A A\} and \{Ten Cate\}, H and \{de Leeuw\}, \{P W\}",

year = "2007",

month = jul,

doi = "10.1111/j.1538-7836.2007.02577.x",

language = "English",

volume = "5",

pages = "1509--15",

journal = "Journal of Thrombosis and Haemostasis",

issn = "1538-7933",

publisher = "Elsevier B.V.",

number = "7",

}

TY - JOUR

T1 - Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients

AU - Dielis, A W J H

AU - Smid, M

AU - Spronk, H M H

AU - Houben, A J H M

AU - Hamulyák, K

AU - Kroon, A A

AU - Ten Cate, H

AU - de Leeuw, P W

PY - 2007/7

Y1 - 2007/7

N2 - BACKGROUND: In hypertensive patients, the activated renin-angiotensin system induces a prothrombotic state resulting from imbalance between coagulation and fibrinolysis. Although blood pressure cannot be regulated in therapy-resistant hypertensive patients, they may still be responsive to medication that attenuates the renin-angiotensin system.OBJECTIVE: our objective was to study possible attenuating properties of angiotensin II type 1 receptor blockers (AT1RBs) on the prothrombotic state in therapy-resistant hypertensive patients, focusing on parameters of fibrinolysis and coagulation.METHODS: Fourteen therapy-resistant hypertensive patients received AT1RB eprosartan infusion (45 and 150 microg kg(-1)) (study group), and 33 therapy-resistant hypertensive patients received saline (0.9%) infusion (control group) prior to renal angiography. Baseline values of parameters of coagulation and fibrinolysis were set at 1.00, and relative changes were calculated.RESULTS: Plasminogen activator inhibitor type 1 (PAI-1) antigen showed non-significant decreases in both the study group (arterial 1.00-0.45, venous 1.00-0.42) and control group (arterial 1.00-0.84, venous 1.00-0.88). PAI-1 activity significantly decreased in the study group (arterial 1.00-0.72, venous 1.00-0.71) and control group (arterial 1.00-0.83, venous 1.00-0.94). In the study group, tissue-type plasminogen activator (t-PA) antigen decreased significantly (arterial 1.00-0.62, venous 1.00-0.67), whereas t-PA activity significantly increased (arterial 1.00-6.15, venous 1.00-2.66). In the control group, t-PA antigen remained unchanged. No changes were observed in blood pressure during and after infusion of eprosartan.CONCLUSION: Therapy-resistant hypertensive patients show beneficial changes in fibrinolytic activity after infusion of a non-pressor dose of AT1RB.

AB - BACKGROUND: In hypertensive patients, the activated renin-angiotensin system induces a prothrombotic state resulting from imbalance between coagulation and fibrinolysis. Although blood pressure cannot be regulated in therapy-resistant hypertensive patients, they may still be responsive to medication that attenuates the renin-angiotensin system.OBJECTIVE: our objective was to study possible attenuating properties of angiotensin II type 1 receptor blockers (AT1RBs) on the prothrombotic state in therapy-resistant hypertensive patients, focusing on parameters of fibrinolysis and coagulation.METHODS: Fourteen therapy-resistant hypertensive patients received AT1RB eprosartan infusion (45 and 150 microg kg(-1)) (study group), and 33 therapy-resistant hypertensive patients received saline (0.9%) infusion (control group) prior to renal angiography. Baseline values of parameters of coagulation and fibrinolysis were set at 1.00, and relative changes were calculated.RESULTS: Plasminogen activator inhibitor type 1 (PAI-1) antigen showed non-significant decreases in both the study group (arterial 1.00-0.45, venous 1.00-0.42) and control group (arterial 1.00-0.84, venous 1.00-0.88). PAI-1 activity significantly decreased in the study group (arterial 1.00-0.72, venous 1.00-0.71) and control group (arterial 1.00-0.83, venous 1.00-0.94). In the study group, tissue-type plasminogen activator (t-PA) antigen decreased significantly (arterial 1.00-0.62, venous 1.00-0.67), whereas t-PA activity significantly increased (arterial 1.00-6.15, venous 1.00-2.66). In the control group, t-PA antigen remained unchanged. No changes were observed in blood pressure during and after infusion of eprosartan.CONCLUSION: Therapy-resistant hypertensive patients show beneficial changes in fibrinolytic activity after infusion of a non-pressor dose of AT1RB.

KW - Acrylates/pharmacology

KW - Adult

KW - Aged

KW - Angiotensin II Type 1 Receptor Blockers/pharmacology

KW - Blood Coagulation/drug effects

KW - Case-Control Studies

KW - Drug Resistance

KW - Endothelial Cells/drug effects

KW - Female

KW - Fibrinolysis/drug effects

KW - Humans

KW - Hypertension/blood

KW - Imidazoles/pharmacology

KW - Male

KW - Middle Aged

KW - Thiophenes/pharmacology

U2 - 10.1111/j.1538-7836.2007.02577.x

DO - 10.1111/j.1538-7836.2007.02577.x

M3 - Article

C2 - 17425665

SN - 1538-7933

VL - 5

SP - 1509

EP - 1515

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

IS - 7

ER -

Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this